Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Cell Proteomics ; 17(9): 1685-1701, 2018 09.
Article in English | MEDLINE | ID: mdl-29844232

ABSTRACT

Tuberculosis (TB) continues to be an important public health threat worldwide, due in part to drug resistant Mycobacterium tuberculosis (Mtb) strains. The United States recently reported a shortage of isoniazid (INH), which could drive higher INH resistance rates. Changes in the Mtb proteome before and after acquisition of INH resistance in a clean genetic background remain understudied and may elucidate alternate drug targets. Here, we focused on Mtb clonal strains to characterize the consequences of INH resistance on mycobacterial metabolism. Proteomic analysis was conducted by liquid-chromatography tandem mass spectrometry (LC-MS/MS) of cellular and secreted fractions, followed by a normalized spectral counting (NSAF) analysis (data are available via ProteomeXchange with identifier PXD009549). Two different Mtb clonal pairs representing a specific genetic lineage (one clinical and one generated in the laboratory) but sharing a katG mutation associated with INH resistance, were used in our analysis. Overall, we found 26 Mtb proteins with altered abundances after acquisition of INH resistance across both Mtb genetic lineages studied. These proteins were involved in ATP synthesis, lipid metabolism, regulatory events, and virulence, detoxification, and adaptation processes. Proteomic findings were validated by Western blotting analyses whenever possible. Mycolic acid (MA) analysis through LC/MS in the clonal Mtb pairs did not reveal a common trend in the alteration of these fatty acids across both INHr strains but revealed a significant reduction in levels of the two more abundant α-MA features in the clinical INHr strain. Interestingly, the clinical clonal pair demonstrated more variation in the abundance of the proteins involved in the FAS II pathway. Together, the proteomic and lipidomic data highlight the identification of potential drug targets such as alternative lipid biosynthetic pathways that may be exploited to combat clinically relevant Mtb INHr strains.


Subject(s)
Drug Resistance, Bacterial/drug effects , Isoniazid/pharmacology , Mycobacterium tuberculosis/drug effects , Bacterial Proteins/metabolism , Energy Metabolism/drug effects , Fatty Acids/biosynthesis , Lipoproteins/metabolism , Mutation/genetics , Mycobacterium tuberculosis/pathogenicity , Mycolic Acids/metabolism , Oxidation-Reduction , S-Adenosylmethionine/metabolism , Transcription, Genetic/drug effects , Virulence/drug effects
2.
PLoS One ; 11(11): e0166807, 2016.
Article in English | MEDLINE | ID: mdl-27893795

ABSTRACT

In the last decade, there were 10 million new tuberculosis cases per year globally. Around 9.5% of these cases were caused by isoniazid resistant (INHr) Mycobacterium tuberculosis (Mtb) strains. Although isoniazid resistance in Mtb is multigenic, mutations in the catalase-peroxidase (katG) gene predominate among the INHr strains. The effect of these drug-resistance-conferring mutations on Mtb fitness and virulence is variable. Here, we assessed differences in bacterial growth, immune response and pathology induced by Mtb strains harboring mutations at the N-terminus of the katG gene. We studied one laboratory and one clinically isolated Mtb clonal pair from different genetic lineages. The INHr strain in each pair had one and two katG mutations with significantly reduced levels of the enzyme and peroxidase activity. Both strains share the V1A mutation, while the double mutant clinical INHr had also the novel E3V katG mutation. Four groups of C57BL/6 mice were infected with one of the Mtb strains previously described. We observed a strong reduction in virulence (reduced bacterial growth), lower induction of proinflammatory cytokines and significantly reduced pathology scores in mice infected with the clinical INHr strain compared to the infection caused by its INHs progenitor strain. On the other hand, there was a subtle reduction of bacteria growth without differences in the pathology scores in mice infected with the laboratory INHr strain. Our results also showed distinct alkyl-hydroperoxidase C (AhpC) levels in the katG mutant strains, which could explain the difference in the virulence profile observed. The difference in the AhpC levels between clonal strains was not related to a genetic defect in the gene or its promoter. Cumulatively, our results indicate that the virulence, pathology and fitness of INHr strains could be negatively affected by multiple mutations in katG, lack of the peroxidase activity and reduced AhpC levels.


Subject(s)
Bacterial Proteins/genetics , Catalase/genetics , Drug Resistance, Bacterial/genetics , Isoniazid/pharmacology , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/pathogenicity , Animals , Antitubercular Agents/pharmacology , Bacterial Proteins/metabolism , Catalase/metabolism , Cytokines/metabolism , Drug Resistance, Bacterial/drug effects , Female , Lung/microbiology , Lung/pathology , Mice, Inbred C57BL , Mutation , Mycobacterium tuberculosis/genetics , Peroxidases/genetics , Peroxidases/metabolism , Tuberculosis/microbiology , Tuberculosis/pathology
3.
Proteomics ; 16(9): 1376-80, 2016 05.
Article in English | MEDLINE | ID: mdl-26929115

ABSTRACT

We determined differences in the protein abundance among two isogenic strains of Mycobacterium tuberculosis (Mtb) with different Isoniazid (INH) susceptibility profiles. The strains were isolated from a pulmonary tuberculosis patient before and after drug treatment. LC-MS/MS analysis identified 46 Mtb proteins with altered abundance after INH resistance acquisition. Protein abundance comparisons were done evaluating the different bacterial cellular fractions (membrane, cytosol, cell wall and secreted proteins). MS data have been deposited to the ProteomeXchange with identifier PXD002986.


Subject(s)
Antitubercular Agents/pharmacology , Drug Resistance, Bacterial/genetics , Gene Expression Regulation, Bacterial/drug effects , Isoniazid/pharmacology , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/genetics , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Catalase/genetics , Catalase/metabolism , Gene Expression Profiling , Gene Ontology , Genotype , Humans , Microbial Sensitivity Tests , Molecular Sequence Annotation , Mutation , Mycobacterium tuberculosis/isolation & purification , Mycobacterium tuberculosis/metabolism , Tuberculosis, Pulmonary/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL
...